Camellia polypeptide-containing oil-soluble polypeptide composition with cellular-grade anti-aging effect as well as preparation method and application of camellia polypeptide-containing oil-soluble polypeptide composition

Abstract

The invention provides an oil-soluble polypeptide composition containing camellia polypeptide and having a cellular-grade anti-aging effect as well as a preparation method and application of the oil-soluble polypeptide composition, and particularly relates to the technical field of cosmetic intermediates. The outside of the oil-soluble polypeptide composition is coated with a phospholipid membrane, and a polypeptide-supramolecular complex is embedded into the phospholipid membrane; the polypeptide-supramolecular complex is obtained by coating a supramolecular solution of polypeptide with first phospholipid and then freeze-drying. The oil-soluble polypeptide composition realizes efficient solubilization and stable loading of polypeptide in a pure oil system. Polypeptide is dissolved by a supramolecular solvent and freeze-dried to form a polypeptide-supramolecular complex, so that exposure of hydrophilic groups of the polypeptide-supramolecular complex is remarkably reduced, and fat solubility is improved; the outer phospholipid membrane not only forms a compact hydrophobic protective barrier, effectively isolates a water-phase environment, inhibits degradation reactions such as hydrolysis and oxidation of polypeptide and improves chemical stability and shelf life, but also serves as a lipid material with excellent biocompatibility, enhances affinity of the composition and a skin cuticle lipid structure and synergistically promotes transdermal permeation of polypeptide.

Description

Technical Field

[0001] This invention relates to the field of cosmetic intermediates technology, and in particular to an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects, its preparation method, and its application. Background Technology

[0002] Due to their high bioactivity and safety, peptides have become a core active ingredient in anti-aging cosmetics. However, their application faces three major technical challenges: First, water-soluble peptides are difficult to dissolve in pure oil-based systems, easily agglomerating and precipitating, leading to product turbidity or layering; second, peptides are unstable in aqueous environments, easily undergoing degradation reactions such as hydrolysis and oxidation, affecting activity and shelf life; third, water-soluble peptides are highly hydrophilic, making it difficult to penetrate the lipid barrier of the stratum corneum, resulting in low transdermal permeability and poor bioavailability.

[0003] Existing technologies often employ methods such as solubilization with co-solvents or surfactant formulations to improve solubility, but these methods suffer from poor compatibility, high irritation, and insufficient stability. While some lipid carriers can enhance permeability, they are mostly dispersed in the aqueous phase and cannot be directly used in oily systems, and they also exhibit low encapsulation efficiency and are prone to leakage. Therefore, there is an urgent need for a technical solution that can achieve highly efficient oil solubility of peptides, stable storage, and significantly improved transdermal performance.

[0004] In view of this, the present invention is hereby proposed. Summary of the Invention

[0005] The purpose of this invention is to provide an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects, its preparation method and application, aiming to solve at least one of the above-mentioned technical problems in the prior art.

[0006] In order to achieve the above-mentioned objectives of the present invention, the following technical solution is adopted: The first aspect of the present invention provides an oil-soluble polypeptide composition containing camellia polypeptide with cellular-level anti-aging effects, which is externally coated with a phospholipid membrane and has a polypeptide-supramolecular complex embedded inside the phospholipid membrane; wherein the polypeptide-supramolecular complex is obtained by freeze-drying a first phospholipid coated with a supramolecular solution of the polypeptide; the supramolecular solvent is composed of a hydrogen donor and a hydrogen acceptor; and the phospholipid membrane is formed of a second phospholipid.

[0007] Furthermore, the oil-soluble polypeptide composition comprises, by weight, 13.5-24 parts of the second phospholipid and 12.51-76 parts of the polypeptide-supramolecular complex.

[0008] In the polypeptide-supramolecular complex, the polypeptide is present in parts by weight of 0.01 to 10, the supramolecular solvent is present in parts by weight of 10 to 60, and the first phospholipid is present in parts by weight of 2.5 to 6.

[0009] Preferably, the mass ratio of the polypeptide to the phospholipid is 1:(30~50).

[0010] Preferably, in the polypeptide-supramolecular complex, the mass ratio of the polypeptide to the supramolecular solvent is 1:(50~100).

[0011] Further, the polypeptide includes at least one of octapeptide-1, glutathione, carnosine, nonapeptide-1, heptapeptide-3, hexapeptide-11, hexapeptide-9, oligopeptide-1, oligopeptide-3, oligopeptide-5, oligopeptide-6, tripeptide-1, tripeptide-1 copper (blue copper peptide), tripeptide-3, tripeptide-5, decapeptide-4, tetrapeptide-4, tetrapeptide-7, pentapeptide-18, pentapeptide-4, myristoyl pentapeptide-11, copper peptide-2, stearoyl tripeptide-1, acetyl heptapeptide-4, acetyl hexapeptide-3, acetyl hexapeptide-8, acetyl tetrapeptide-5, acetyl carnosine, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, palmitoyl pentapeptide-4, palmitoyl hexapeptide-12, and camellia polypeptide.

[0012] Preferably, the polypeptide is nonapeptide-1, palmitoyl tetrapeptide-7, palmitoyl pentapeptide-4, and camellia polypeptide.

[0013] Preferably, the mass ratio of the nonapeptide-1, the palmitoyl tetrapeptide-7, and the palmitoyl pentapeptide-4 is 528.4:40.6:2.18.

[0014] Preferably, the supramolecular solvent is composed of a hydrogen donor and a hydrogen acceptor in a molar ratio of (1~5):1.

[0015] And / or, the hydrogen donor is an amino acid compound and / or a carboxylic acid compound.

[0016] And / or, the amino acid compounds include glycine and / or L-serine.

[0017] And / or, the carboxylic acid compound includes at least one of isostearic acid, decanoic acid, and lactic acid.

[0018] And / or, the hydrogen acceptor is an alkaloid.

[0019] And / or, the alkaloids include at least one of matrine, oxymatrine, betaine, carnitine, and choline.

[0020] Preferably, the hydrogen donor includes at least one of isostearic acid and decanoic acid; the hydrogen acceptor includes at least one of matrine and oxymatrine.

[0021] Furthermore, the phospholipids include at least one of soybean lecithin, egg yolk lecithin, hydrogenated lecithin, phosphatidylcholine, phosphatidylethanolamine, dipalmitoylphosphatidylcholine (DPPC), and distearate phosphatidylcholine (DSPC).

[0022] Preferably, the soybean lecithin has a phosphatidylcholine content of ≥90%.

[0023] Furthermore, the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects further includes a stabilizer in parts by weight of 1 to 15 parts.

[0024] Preferably, the stabilizer includes at least one of glycerol tri(ethylhexanoate) ester (GTCC), squalane, camellia oil, vitamin E, and disodium EDTA.

[0025] Preferably, the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects further includes 2 to 40 parts by weight of an adjuvant.

[0026] Preferably, the adjuvant includes at least one selected from 1,2-hexanediol, pentanediol, and butanediol.

[0027] The second aspect of this invention provides a method for preparing an oil-soluble polypeptide composition containing camellia polypeptide with cellular-level anti-aging effects. The method involves dissolving the polypeptide in a supramolecular solvent to obtain a supramolecular solution of the polypeptide; adding a first phospholipid to the supramolecular solution of the polypeptide and mixing thoroughly; then freeze-drying the mixture to obtain the polypeptide-supramolecular complex; mixing a second phospholipid, optional auxiliaries, and optional stabilizers to obtain a phospholipid solution; and finally adding the polypeptide-supramolecular complex to the phospholipid solution and mixing thoroughly to obtain the oil-soluble polypeptide composition containing camellia polypeptide with cellular-level anti-aging effects.

[0028] Furthermore, the mass ratio of the first phospholipid to the second phospholipid is 1:(2~12).

[0029] Furthermore, the supramolecular solvent is prepared by grinding the hydrogen donor and hydrogen acceptor and dispersing them in an alcohol-water solution, and then reacting them under nitrogen protection to obtain the supramolecular solvent.

[0030] Preferably, the concentration of alcohol in the aqueous alcohol solution is 50-70 wt%.

[0031] Preferably, the alcohol in the aqueous alcohol solution includes at least one of methanol, ethanol, propylene glycol, and butanediol.

[0032] Preferably, the reaction temperature is 20~45℃ and the time is 20~36h.

[0033] The third aspect of this invention provides the application of the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects in the preparation of cosmetics.

[0034] Furthermore, the amount of oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects added to cosmetics is 0.5~10wt.

[0035] Preferably, the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects is added during the cold preparation stage.

[0036] Preferably, the temperature during the cold preparation stage is below 50°C.

[0037] Compared with the prior art, the present invention has at least the following beneficial effects: This invention provides an oil-soluble peptide composition containing camellia peptides with cellular-level anti-aging effects. Through a phospholipid membrane-encapsulated peptide-supramolecular complex structure, it achieves highly efficient solubilization and stable loading of peptides in pure oil systems. Specifically, the peptides are dissolved in a supramolecular solvent and freeze-dried to form a peptide-supramolecular complex, significantly reducing the exposure of their hydrophilic groups and improving lipophilicity. The outer phospholipid membrane not only forms a dense hydrophobic protective barrier, effectively isolating the aqueous environment and inhibiting degradation reactions such as hydrolysis and oxidation of the peptides, thus improving chemical stability and shelf life, but also, as a biocompatible lipid material, enhances the affinity of the composition with the lipid structure of the stratum corneum of the skin, synergistically promoting transdermal penetration of the peptides. This structure achieves transparent dispersion and efficient delivery of water-soluble peptides in various oily matrices without relying on traditional high-volume solubilizers or chemical penetration enhancers, significantly improving their bioavailability.

[0038] The preparation method provided by this invention involves first dissolving the peptide in a supramolecular solvent, effectively disrupting intermolecular hydrogen bonds and reducing its polarity, thus significantly improving its dispersibility in nonpolar environments. A first phospholipid is then added and thoroughly mixed with the peptide-supramolecular solution, followed by freeze-drying. This allows the peptide to be stably embedded in the phospholipid matrix, forming a homogeneous peptide-supramolecular complex. This prevents peptide aggregation and precipitation and provides a lipid interface basis for subsequent encapsulation. Next, a second phospholipid, along with auxiliaries and stabilizers, is heated and dissolved to form a highly fluid phospholipid solution. Finally, the complex is slowly added and homogenized, allowing the phospholipids to spontaneously coat the complex surface, constructing a complete and stable core-shell structure. This process eliminates the need for toxic organic solvents, operates under mild conditions, avoids thermal degradation and structural damage to the peptide, achieves high encapsulation efficiency and long-term storage stability, and imparts excellent oil solubility and transdermal penetration enhancement to the final product, facilitating direct application in various pure oil-based cosmetics.

[0039] The application provided by this invention, given the advantages of the above-mentioned oil-soluble polypeptide composition containing camellia polypeptide with cellular-level anti-aging effects, allows the composition to be directly added to anhydrous or high-oil-phase cosmetics such as facial oils and facial oils, maintaining the product's transparency and uniformity, without the need for additional solubilizers or chemical penetration enhancers, and ensuring high safety. It is suitable for the development of high-end anti-aging skincare products, achieving a triple breakthrough in the efficacy of polypeptide ingredients in oily cosmetics: high stability, high penetration, and high compatibility. Attached Figure Description

[0040] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0041] Figure 1 The results of the 24-hour stability test for Example 1 are shown. Figure 2 The results are the 30-day stability test results for Example 1; Figure 3 Raman spectra of human skin in vivo; Figure 4 The image shows the Raman spectrum of palmitoyl tetrapeptide-7. Figure 5 The image shows the Raman spectrum of camellia polypeptide. Figure 6 The image shows the Raman spectrum of palmitoyl pentapeptide-4. Figure 7 The image shows the Raman spectrum of nonapeptide-1. Figure 8 Bar charts showing the relative permeability of Example 1 and Comparative Example 6; Figure 9 A bar chart showing the COL1 MFI values ​​in fibroblasts; Figure 10 A summary chart of COL1 content (magnification 200). Detailed Implementation

[0042] To make the objectives, technical solutions, and advantages of the present invention clearer, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments.

[0043] In the following, the terms “comprising,” “having,” and their cognates, which may be used in various embodiments of the invention, are intended only to indicate a particular feature, number, step, operation, element, component, or combination thereof, and should not be construed as excluding, firstly, the presence of one or more other features, numbers, steps, operations, elements, components, or combinations thereof, or adding the possibility of one or more features, numbers, steps, operations, elements, components, or combinations thereof.

[0044] The first aspect of the present invention provides an oil-soluble polypeptide composition containing camellia polypeptide with cellular-level anti-aging effects, which is externally coated with a phospholipid membrane and has a polypeptide-supramolecular complex embedded inside the phospholipid membrane; wherein the polypeptide-supramolecular complex is obtained by freeze-drying a first phospholipid coated with a supramolecular solution of the polypeptide; the supramolecular solvent is composed of a hydrogen donor and a hydrogen acceptor; and the phospholipid membrane is formed of a second phospholipid.

[0045] This invention provides an oil-soluble peptide composition containing camellia peptides with cellular-level anti-aging effects. Through a phospholipid membrane-encapsulated peptide-supramolecular complex structure, it achieves highly efficient solubilization and stable loading of peptides in pure oil systems. Specifically, the peptides are dissolved in a supramolecular solvent and freeze-dried to form a peptide-supramolecular complex, significantly reducing the exposure of their hydrophilic groups and improving lipophilicity. The outer phospholipid membrane not only forms a dense hydrophobic protective barrier, effectively isolating the aqueous environment and inhibiting degradation reactions such as hydrolysis and oxidation of the peptides, thus improving chemical stability and shelf life, but also, as a biocompatible lipid material, enhances the affinity of the composition with the lipid structure of the stratum corneum of the skin, synergistically promoting transdermal penetration of the peptides. This structure achieves transparent dispersion and efficient delivery of water-soluble peptides in various oily matrices without relying on traditional high-volume solubilizers or chemical penetration enhancers, significantly improving their bioavailability.

[0046] Cellular-level anti-aging efficacy refers to methods that differ from physical covering and moisturizing that only act on the skin surface. It targets skin cells (such as dermal fibroblasts and epidermal keratinocytes) as the core target and achieves the effect of delaying the aging process and reversing the decline of cell function at the cellular level by regulating cellular physiological metabolism, repairing aging-related structural damage to cells, or activating cellular anti-aging signaling pathways. This results in improving signs of aging such as wrinkles, sagging, and dullness.

[0047] Furthermore, the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects comprises, by weight, 13.5-24 parts of the second phospholipid and 12.51-76 parts of the polypeptide-supramolecular complex.

[0048] In the polypeptide-supramolecular complex, the polypeptide is present in parts by weight of 0.01 to 10, the supramolecular solvent is present in parts by weight of 10 to 60, and the first phospholipid is present in parts by weight of 2.5 to 6.

[0049] Typical, but not limiting, the oil-soluble polypeptide composition containing camellia polypeptide with cellular-level anti-aging effects, by weight, may contain, for example, 13.5 parts, 15 parts, 20 parts, or 24 parts, or any value within the range of 13.5-24 parts; and the polypeptide-supramolecular complex may contain, for example, 12.51 parts, 20 parts, 30 parts, 40 parts, 50 parts, 60 parts, or 70 parts, or any value within the range of 12.51-76 parts. In the polypeptide-supramolecular complex, the weight parts of the polypeptide can be, for example, 0.01 parts, 2 parts, 4 parts, 6 parts, 8 parts, or 10 parts, or any value within the range of 0.01 to 10 parts; the weight parts of the supramolecular solvent can be, for example, 10 parts, 20 parts, 30 parts, 40 parts, 50 parts, or 60 parts, or any value within the range of 10 to 60 parts; and the weight parts of the first phospholipid can be, for example, 2.5 parts, 3 parts, 4 parts, 5 parts, or 6 parts, or any value within the range of 2.5 to 6 parts.

[0050] Preferably, the mass ratio of the polypeptide to the phospholipid is 1:(30~50). If the phospholipid content is too low, the encapsulation system will be unstable, and the polypeptide may leak out during storage, thus precipitating out of the formula and making the formula opaque. If the phospholipid content is too high, there is a risk of discoloration.

[0051] It should be noted that, unless otherwise specified, when “the mass of phospholipids” is mentioned alone in this article, it refers to the total amount of the first phospholipid and the second phospholipid, and when “phospholipids” is mentioned alone, it refers to the first phospholipid and / or the second phospholipid.

[0052] Typically, but not limitingly, the mass ratio of the polypeptide to the phospholipid can be, for example, 1:30, 1:35, 1:40, 1:45 or 1:50, or any ratio in the range of 1:(30~50).

[0053] Preferably, in the polypeptide-supramolecular complex, the mass ratio of polypeptide to supramolecular solvent is 1:(50~100). If the supramolecular solvent content is too low, the polypeptide will not be completely dissolved, thus making it impossible to carry out the subsequent phospholipid encapsulation process. At the same time, if its content is too low, the polypeptide's permeability may be insufficient. If the supramolecular solvent content is too high, the system will easily cause unstable phenomena such as layering and discoloration.

[0054] Typically, but not limitingly, in the polypeptide-supramolecular complex, the mass ratio of the polypeptide to the supramolecular solvent can be, for example, 1:50, 1:60, 1:70, 1:80, 1:90 or 1:100, or any ratio in the range of 1:(50~100).

[0055] Further, the polypeptide includes at least one of octapeptide-1, glutathione, carnosine, nonapeptide-1, heptapeptide-3, hexapeptide-11, hexapeptide-9, oligopeptide-1, oligopeptide-3, oligopeptide-5, oligopeptide-6, tripeptide-1, tripeptide-1 copper (blue copper peptide), tripeptide-3, tripeptide-5, decapeptide-4, tetrapeptide-4, tetrapeptide-7, pentapeptide-18, pentapeptide-4, myristoyl pentapeptide-11, copper peptide-2, stearoyl tripeptide-1, acetyl heptapeptide-4, acetyl hexapeptide-3, acetyl hexapeptide-8, acetyl tetrapeptide-5, acetyl carnosine, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, palmitoyl pentapeptide-4, palmitoyl hexapeptide-12, and camellia polypeptide.

[0056] Preferably, the polypeptide is nonapeptide-1, palmitoyl tetrapeptide-7, palmitoyl pentapeptide-4, and camellia polypeptide.

[0057] Preferably, the mass ratio of the nonapeptide-1, the palmitoyl tetrapeptide-7, and the palmitoyl pentapeptide-4 is 528.4:40.6:2.18.

[0058] Preferably, the supramolecular solvent is composed of hydrogen donors and hydrogen acceptors in a molar ratio of (1~5):1, which dissolves the polypeptide. The freeze-drying process further increases the interaction between the polypeptide and a large number of hydrogen bonds in the supramolecular structure, making it compatible with phospholipids and thus compatible with more oils, enabling its application in pure oil systems.

[0059] Typically, but not limitingly, the supramolecular solvent consists of a hydrogen donor and a hydrogen acceptor in a molar ratio, for example, 1:1, 2:1, 3:1, 4:1, or 5:1, or any molar ratio in the range of (1 to 5):1.

[0060] And / or, the hydrogen donor is an amino acid compound and / or a carboxylic acid compound.

[0061] And / or, the amino acid compounds include glycine and / or L-serine.

[0062] And / or, the carboxylic acid compound includes at least one of isostearic acid, decanoic acid, and lactic acid.

[0063] And / or, the hydrogen acceptor is an alkaloid.

[0064] And / or, the alkaloids include at least one of matrine, oxymatrine, betaine, carnitine, and choline.

[0065] Preferably, the hydrogen donor includes at least one of isostearic acid and decanoic acid; the hydrogen acceptor includes at least one of matrine and oxymatrine. Further, the phospholipid includes at least one of soybean lecithin, egg yolk lecithin, hydrogenated lecithin, phosphatidylcholine, phosphatidylethanolamine, dipalmitoylphosphatidylcholine (DPPC), and distearate phosphatidylcholine (DSPC).

[0066] Preferably, the soybean lecithin has a phosphatidylcholine content of ≥90%.

[0067] Furthermore, the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects further includes a stabilizer in parts by weight of 1 to 15 parts.

[0068] Preferably, the stabilizer comprises at least one of triglyceride (ethylhexanoate), caprylic / capric triglyceride (GTCC), squalane, camellia oil, vitamin E, and disodium EDTA. The stabilizer can adjust the polarity and viscosity of the system, enhance the compatibility of the composition with different oil-phase matrices, prevent stratification or precipitation due to polarity differences, and improve physical stability. These stabilizers, together with phospholipid membranes, supramolecular solvents, and auxiliaries, construct a physically and chemically stable microenvironment, ensuring that the peptides maintain their dissolved state, structural integrity, and biological activity in the pure oil system for a long period.

[0069] Preferably, the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects further includes 2 to 40 parts by weight of an adjuvant.

[0070] Preferably, the adjuvant includes at least one of 1,2-hexanediol, pentanediol, and butylene glycol. The adjuvant possesses both polar solvent properties, promoting the initial dissolution and dispersion of peptides in supramolecular solvents and enhancing the homogeneity of the peptide-supramolecular solution; and good moisturizing and penetration-promoting abilities, enabling it to adjust the polarity balance of the composition without affecting the oil solubility of the system, thus improving its compatibility and dispersion stability in different oil matrices. Furthermore, these polyols also have antibacterial and preservative functions, helping to improve the microbial safety of the final product. During the preparation process, the adjuvant, phospholipids, and stabilizers work together to not only help form a well-flowing and stable phospholipid solution, but also promote the uniform coating of the peptide-supramolecular complex by phospholipids during composition construction, thereby improving the encapsulation efficiency and the overall stability of the formulation, ensuring that the peptide maintains high loading and bioavailability in pure oil systems over a long period.

[0071] The second aspect of this invention provides a method for preparing an oil-soluble polypeptide composition containing camellia polypeptide with cellular-level anti-aging effects. The method involves dissolving the polypeptide in a supramolecular solvent to obtain a supramolecular solution of the polypeptide; adding a first phospholipid to the supramolecular solution of the polypeptide and mixing thoroughly; then freeze-drying the mixture to obtain the polypeptide-supramolecular complex; mixing a second phospholipid, optional auxiliaries, and optional stabilizers to obtain a phospholipid solution; and finally adding the polypeptide-supramolecular complex to the phospholipid solution and mixing thoroughly to obtain the oil-soluble polypeptide composition containing camellia polypeptide with cellular-level anti-aging effects.

[0072] The preparation method provided by this invention involves first dissolving the peptide in a supramolecular solvent, effectively disrupting intermolecular hydrogen bonds and reducing its polarity, thus significantly improving its dispersibility in nonpolar environments. A first phospholipid is then added and thoroughly mixed with the peptide-supramolecular solution, followed by freeze-drying. This allows the peptide to be stably embedded in the phospholipid matrix, forming a homogeneous peptide-supramolecular complex. This prevents peptide aggregation and precipitation and provides a lipid interface basis for subsequent encapsulation. Next, a second phospholipid, along with auxiliaries and stabilizers, is heated and dissolved to form a highly fluid phospholipid solution. Finally, the complex is slowly added and homogenized, allowing the phospholipids to spontaneously coat the complex surface, constructing a complete and stable core-shell structure. This process eliminates the need for toxic organic solvents, operates under mild conditions, avoids thermal degradation and structural damage to the peptide, achieves high encapsulation efficiency and long-term storage stability, and imparts excellent oil solubility and transdermal penetration enhancement to the final product, facilitating direct application in various pure oil-based cosmetics.

[0073] Furthermore, the mass ratio of the first phospholipid to the second phospholipid is 1:(2~12).

[0074] Furthermore, the supramolecular solvent is prepared by grinding the hydrogen donor and hydrogen acceptor and dispersing them in an alcohol-water solution, and then reacting them under nitrogen protection to obtain the supramolecular solvent.

[0075] Preferably, the concentration of alcohol in the aqueous alcohol solution is 50-70 wt%.

[0076] Preferably, the alcohol in the aqueous alcohol solution includes at least one of methanol, ethanol, propylene glycol, and butanediol.

[0077] Preferably, the reaction temperature is 20~45℃ and the time is 20~36h.

[0078] Typically, but not limitingly, the reaction temperature can be, for example, 20°C, 35°C, 37°C, 39°C, 41°C, 43°C, or 45°C, or any value within the range of 35°C to 45°C; the reaction time can be, for example, 20h, 22h, 24h, 26h, 28h, 30h, 32h, 34h, or 36h, or any value within the range of 20h to 36h.

[0079] The third aspect of this invention provides the application of the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects in the preparation of cosmetics.

[0080] The application provided by this invention, given the advantages of the above-mentioned oil-soluble polypeptide composition containing camellia polypeptide with cellular-level anti-aging effects, allows the composition to be directly added to anhydrous or high-oil-phase cosmetics such as facial oils and facial oils, maintaining the product's transparency and uniformity, without the need for additional solubilizers or chemical penetration enhancers, and ensuring high safety. It is suitable for the development of high-end anti-aging skincare products, achieving a triple breakthrough in the efficacy of polypeptide ingredients in oily cosmetics: high stability, high penetration, and high compatibility.

[0081] Furthermore, the amount of oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects added to cosmetics is 0.5~10wt.

[0082] Preferably, the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects is added during the cold preparation stage.

[0083] Preferably, the temperature during the cold preparation stage is below 50°C.

[0084] The present invention is further illustrated below with specific embodiments and comparative examples. However, it should be understood that these embodiments are merely for illustrative purposes and should not be construed as limiting the invention in any way. Unless otherwise specified, the raw materials used in the embodiments and comparative examples of the present invention were carried out under conventional conditions or conditions recommended by the manufacturer. Reagents or instruments used, unless otherwise specified, are all commercially available conventional products.

[0085] Example 1 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The specific preparation steps are as follows: 1. Weigh 7 parts of matrine and 38 parts of isostearic acid, then grind them in a vibratory mill at room temperature for 30 minutes. The ground sample is then dispersed in 25 parts of ethanol aqueous solution (concentration of 70 wt%) to obtain a uniform liquid. Continue stirring and reacting at 40℃ and under nitrogen purging for 30 hours to obtain a viscous liquid and obtain a supramolecular solvent.

[0086] 2. Mix supramolecular solvent with 0.5284 parts of nonapeptide-1, 0.0406 parts of palmitoyl pentapeptide-4, 0.00218 parts of palmitoyl tetrapeptide-7, and 0.01 parts of camellia polypeptide. Stir continuously at room temperature to ensure complete dissolution of the polypeptide. Then add 5 parts of soybean lecithin and stir thoroughly to ensure complete dissolution. Finally, freeze dry the mixture using a vacuum freeze dryer to obtain the polypeptide-supramolecular complex.

[0087] 3. Mix and dissolve 15 parts of soybean lecithin and 34.41882 parts of 1,2-hexanediol at 45℃ to obtain a transparent liquid, which is a phospholipid solution.

[0088] 4. Under rapid stirring conditions, the polypeptide-supramolecular complex is slowly added to the phospholipid solution and stirred continuously at room temperature for 1 hour to obtain an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects.

[0089] Example 2 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that matrine is 18.5 parts and isostearic acid is 26.5 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0090] Example 3 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that matrine is 20.6 parts and isostearic acid is 24.4 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0091] Example 4 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that matrine is 11.7 parts and isostearic acid is 33.3 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0092] Example 5 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that matrine is 6.5 parts and isostearic acid is 38.5 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0093] Example 6 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that the amount of matrine is 9.22 parts and the amount of isostearic acid is 50.06 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0094] Example 7 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that the amount of matrine is 8.95 parts and the amount of isostearic acid is 48.95 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0095] Example 8 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that the amount of matrine is 4.61 parts and the amount of isostearic acid is 25.03 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0096] Example 9 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that the amount of matrine is 4.34 parts and the amount of isostearic acid is 24.56 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0097] Example 10 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that the lecithin in step 3 is 11 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0098] Example 11 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that the lecithin in step 3 is 13.5 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0099] Example 12 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that the lecithin in step 3 is 24 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0100] Example 13 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that the lecithin in step 3 is 27 parts. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0101] Example 14 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that matrine is replaced with oxymatrine. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0102] Example 15 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that isostearic acid is replaced with decanoic acid. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0103] Example 16 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that the soybean lecithin is replaced with egg yolk lecithin. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0104] Example 17 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that soybean 1,2-hexanediol is replaced with pentanediol. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0105] Example 18 This embodiment provides an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects. The difference from Example 1 is that 34.41882 parts of 1,2-hexanediol are replaced with 20 parts of 1,2-pentanediol and 14.41882 parts of camellia oil. The remaining raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0106] Example 19 This embodiment provides an oil-soluble polypeptide composition with cell-level anti-aging effects. The difference from Example 1 is that 0.5284 parts of nonapeptide-1, 0.0406 parts of palmitoyl pentapeptide-4, 0.00218 parts of palmitoyl tetrapeptide-7, and 0.01 parts of camellia polypeptide are replaced with 0.5 parts of carnosine and 0.08118 parts of acetyl hexapeptide-8. The remaining raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0107] Example 20 This embodiment provides an oil-soluble polypeptide composition with cell-level anti-aging effects. The difference from Example 1 is that 0.5284 parts of nonapeptide-1, 0.0406 parts of palmitoyl pentapeptide-4, 0.00218 parts of palmitoyl tetrapeptide-7, and 0.01 parts of camellia polypeptide are replaced with 0.6 parts of glutathione and 0.1 parts of palmitoyl tripeptide-5. The remaining raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0108] Example 21 This embodiment provides an oil-soluble polypeptide composition with cell-level anti-aging effects. The difference from Example 1 is that 0.5284 parts of nonapeptide-1, 0.0406 parts of palmitoyl pentapeptide-4, 0.00218 parts of palmitoyl tetrapeptide-7, and 0.01 parts of camellia polypeptide are replaced with 0.1 parts of tripeptide-1, 0.4 parts of tripeptide-3, and 0.5 parts of tripeptide-5. The remaining raw materials and preparation methods are the same as in Example 1 and will not be repeated here.

[0109] Comparative Example 1 This comparative example provides a water-soluble polypeptide solution. 0.5284 parts of nonapeptide-1, 0.0406 parts of palmitoyl pentapeptide-4, 0.00218 parts of palmitoyl tetrapeptide-7, and 0.01 parts of camellia polypeptide were added to 34.41882 parts of 1,2-hexanediol and deionized water, and stirred at room temperature for 60 min to obtain the water-soluble polypeptide solution.

[0110] Comparative Example 2 This comparative example provides a polypeptide composition in which matrine is replaced with arginine compared to Example 1. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0111] Comparative Example 3 This comparative example provides a polypeptide composition in which isostearic acid is replaced with levulinic acid compared to Example 1. The other raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0112] Comparative Example 4 This comparative example provides a polypeptide composition. Compared with Example 1, step 1 is omitted after removing isostearic acid and matrine. The remaining raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0113] Comparative Example 5 This comparative example provides a polypeptide composition. Compared with Example 1, the phospholipids in step 3 are removed. The remaining raw materials and preparation methods are the same as in Example 1, and will not be repeated here.

[0114] Comparative Example 6 This comparative example provides an oil-soluble polypeptide solution with the following components: 0.5284 parts of nonapeptide-1, 0.0406 parts of palmitoyl pentapeptide-4, 0.00218 parts of palmitoyl tetrapeptide-7, 0.01 parts of camellia polypeptide, 5 parts of glyceryl caprylate, 50 parts of ethylhexylglycerol, and 100 parts of caprylic / capric triglyceride. Nonapeptide-1, palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, camellia polypeptide, glyceryl caprylate, and ethylhexylglycerol are thoroughly mixed and stirred for 15 minutes to obtain a mixture. This mixture is then added to caprylic / capric triglyceride and stirred for another 20 minutes to obtain the oil-soluble polypeptide solution.

[0115] Test case The products obtained from the examples and comparative examples were subjected to performance tests, as detailed below: 1. Appearance method: Take the product into a 25mL sample bottle and visually observe the appearance of the product at room temperature and in the absence of direct sunlight. See Table 1 for specific data.

[0116] Among them, "transparent" means that the solution is uniform from top to bottom, and the object behind it can be directly observed through the sample bottle; "layered" means that the solution is not uniform from top to bottom, and the boundary between the two different solutions can be clearly observed; "turbid" means that the solution is not uniform and may contain suspended matter, and the object behind it cannot be directly observed through the sample bottle; "precipitate" means that the upper layer of the solution is transparent and the bottom layer shows obvious solids.

[0117] 2. Stability Test Method: The product was placed in a sample bottle and placed under four conditions: room temperature, -20℃, 45℃, and 4℃, for 72 hours respectively. The appearance changes of the product were visually observed at room temperature and under non-direct sunlight. Specific data are shown in Table 1.

[0118] Among them, stability means that the color, odor, state, transparency and apparent viscosity of the sample did not change visibly after being placed under various conditions and then restored to room temperature, while precipitation means that the appearance becomes cloudy or obvious precipitation occurs.

[0119] Table 1. Appearance and stability test results for each embodiment and comparative example.

[0120] 3. Oil Compatibility Test: The oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects prepared in Example 1 and the solution prepared in Comparative Example 6 were taken and dispersed in different types of commonly used cosmetic oils at an addition ratio of 5%. The commonly used cosmetic oils used in this experiment were GTCC, squalane, isosorbide, octyl dodecanol, cetearyl alcohol, isononyl isononanoate, isopropyl lauroyl sarcosinate, diisopropyl sebacic acid, camellia oil, and perilla seed oil, a total of 10 kinds, covering polyols, polar oils, and non-polar oils. The clarity and transparency of the solution and the accelerated stability after being placed at high temperature of 45°C and low temperature of 4°C for 72 hours were observed. The specific data are shown in Table 2.

[0121] Table 2 Comparison of compatibility between Example 1 and Comparative Example 6

[0122] 4. Formulation stability test: The oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effect prepared in Example 1 was added to camellia seed oil at a ratio of 2%. Then, it was placed under six conditions: room temperature, -20℃, 45℃, 4℃, light, and hot and cold cycling for 24 hours and 30 days. After the end of the test, the appearance changes of the product were visually observed at room temperature and under non-direct sunlight.

[0123] Figure 1 The results of the 24-hour stability test for Example 1 are as follows: Figure 1 It can be seen that, under the above test conditions, the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects all maintained a pale yellow transparent liquid state.

[0124] Figure 2 The results of the 30-day stability test for Example 1 are as follows: Figure 2 It can be seen that, under the above test conditions, the oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects all maintained a pale yellow transparent liquid state.

[0125] Based on the data in Table 1 Figure 1 and Figure 2 It can be seen that the oil-soluble peptides prepared using the method of Example 1 have good stability, high compatibility with various oils and fats, and excellent permeability.

[0126] Examples 2, 3, 4, and 5 demonstrate the effect of different ratios of isostearic acid and matrine on product stability. Within the preferred range, the product remains transparent and stable under all conditions. Too low a ratio of isostearic acid may cause turbidity, while too high a ratio of matrine may cause it to precipitate in solution. Exceeding the preferred range will reduce product stability. Examples 6, 7, 8, and 9 demonstrate the effect of different supramolecular solvents relative to the amount of peptide on product stability. Too low a supramolecular solvent content may cause the peptide to expose hydrophilic groups and precipitate in solution, resulting in system instability. Too high a supramolecular solvent content may pose a risk of layering and discoloration. Examples 10, 11, 12, and 13 demonstrate the effect of different phospholipid ratios on product stability. Too low a phospholipid content may result in incomplete encapsulation, potentially leading to peptide leakage and precipitation during testing. Too high a phospholipid content may increase costs and pose a potential risk of discoloration.

[0127] Figure 1 and Figure 2 This demonstrates that the oil-soluble peptides prepared in Example 1 of this scheme can be conveniently applied to transparent essential oils and can pass conventional cosmetic stability tests; Figure 2 The results show that the oil-soluble peptide prepared in Example 1 of this scheme was tested for 30 days under ambient temperature, -20℃, 45℃, 4℃, light irradiation, and thermal cycling conditions. The appearance remained a pale yellow liquid with no significant changes. The oil-soluble peptide provided by this invention has excellent compatibility with oil-soluble systems and environmental tolerance.

[0128] 5. Transdermal permeability test: To verify the permeation-enhancing effect of the present invention on peptides, confocal Raman spectroscopy was used to detect its in vivo skin penetration. The test method refers to T / SHRH 064-2024, and the in vivo Raman spectrum of the human body was measured (…). Figure 3 ) and the Raman spectra of four polypeptides ( Figure 4 , Figure 5 , Figure 6 and Figure 7 Raman spectroscopy was performed on the forearm region of the subject, and six equally sized 1 1cm 2 Region; Example 1 and Comparative Example 6 were prepared at 2 mg / cm² 2 The peptides were applied to the test area, and Raman spectra of the corresponding peptides on the skin were measured at different time points of 0 h, 1 h, 2 h, 4 h, 6 h, and 8 h, and the relative permeability (%) was calculated.

[0129] Experimental results are as follows Figure 8 The oil-soluble peptides prepared in Example 1 showed significantly higher overall relative permeability at all time points than those in Comparative Example 6 (P<0.001). The supramolecular and phospholipid components synergistically disrupted the ordered arrangement of the phospholipid bilayer, reduced barrier resistance, and effectively improved the transdermal delivery efficiency of the peptides.

[0130] 6. Efficacy Experiment: To verify the promoting effect of this invention on the synthesis and secretion of type I collagen (COL1) in human dermal fibroblasts, the localization of COL1 protein in cells was observed and the changes in expression level were quantitatively analyzed by specifically labeling COL1 protein. Example 1 and Comparative Example 6 were prepared at a peptide concentration of 25 μg / mL as experimental groups. Control groups, positive control groups, and negative control groups were also set up. The specific settings of each control group are as follows: the blank control group was a control group with only sterile cell culture medium and no UVA treatment; the positive control group was a control group with 7 μg / mL VE solution; the negative control group was a blank control group with only sterile cell culture medium and UVA treatment.

[0131] Each experimental group and control group was incubated for 24 hours in human skin fibroblast culture dishes specifically labeled with COL1. The blank control group received no UVA treatment, while the experimental groups, positive control group, and negative control group received UVA at 30 J / cm². 2 Cells were processed and cultured for another 24 hours. The cultured cells were then stained with fluorescence. The fluorescence signal was quantified using weighted brightness calculated by ImageJ software. Images were processed using ImageJ (version 1.54p, National Institutes of Health, USA). The cumulative optical density value IntDen (integrated optical density, IOD) was analyzed, and the mean fluorescence intensity (MFI) and UV damage repair enhancement rate were calculated.

[0132]

[0133]

[0134] The experimental results are shown in Table 3. Figure 9 and Figure 10 (Compared with the UVA group, the positive group, Example 1, and Comparative Example 6 showed significant differences.) This means that a p-value < 0.05 indicates that... A p-value < 0.01 indicates that... The significance of the difference between the blank group and the model group is expressed as &, P value <0.05 is expressed as &, P value <0.01 is expressed as &&). The MFI value of the Example 1 group was significantly higher than that of the negative control group and the comparative example 6 group (P<0.01), and close to that of the positive control group. The oil-soluble polypeptide composition of the present invention can effectively reverse the inhibition of COL1 synthesis induced by UVA, and its ability to promote collagen synthesis and secretion is close to that of the positive control VE; the UV damage repair improvement rate is 2800.00%, which is 4.3 times that of the comparative example 6. The supramolecular layer of the oil-soluble polypeptide composition provided by the present invention can realize the efficient solubilization and stability protection of polypeptides, avoid the aggregation and inactivation of polypeptides in the system, and the phospholipid coating of the outer layer, as a component of the cell membrane, can enhance the affinity of polypeptides for fibroblasts, promote the intracellular uptake of active ingredients, and synergistically achieve collagen synthesis.

[0135] Table 3 Summary of COL1 MFI value data analysis results in fibroblasts

[0136] In summary, this invention dissolves peptides in a specific ratio of supramolecular solvent, uses phospholipids as an interface stabilizer, and, with the help of adjuvants and stabilizers, successfully applies peptides to pure oil systems. It exhibits compatibility with various oils and, more importantly, simultaneously improves the peptides' permeability, greatly enhancing their bioavailability and enabling them to simultaneously meet the application and efficacy requirements in oil products. It offers the following advantages: (1) Oil phase solubilization: After surface treatment by supramolecular technology, the exposure of hydrophilic groups on the surface of the peptide is reduced, so that it can exist stably in phospholipids without precipitation. Phospholipids serve as an interface medium, and the peptide is further applied to various oils. Under the premise of ensuring the transparency of the oil, the peptide is solubilized and applied in various oils such as polyols, polar oils, and non-polar oils. Its stability in transparent essence has been verified through long-term investigation, so that the peptide can be truly applied in pure oil transparent system.

[0137] (2) Achieving penetration enhancement while solubilizing in the oil phase: Most peptides, as hydrophilic molecules, are difficult to penetrate the dense lipid stratum corneum interstitial space, resulting in low bioavailability. This solution stabilizes them in the oil through supramolecular and phospholipid mediators, improving their affinity for the lipid stratum corneum. Furthermore, supramolecular and phospholipids, as penetration-enhancing components, achieve penetration enhancement by disrupting the orderly arrangement of the lipid layer, thus significantly improving the permeability of the peptides in this solution and greatly enhancing their bioavailability. This invention does not introduce any toxic or harmful organic solvents, nor does it introduce chemical penetration enhancers such as azone, which are unwelcome in cosmetics, achieving the safe and effective application of peptides in a pure oil system.

[0138] Finally, it should be noted that the above-described embodiments are merely specific implementations of the present invention, used to illustrate the technical solutions of the present invention, and not to limit it. The scope of protection of the present invention is not limited thereto. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that any person skilled in the art can still modify or easily conceive of changes to the technical solutions described in the foregoing embodiments within the technical scope disclosed in the present invention, or make equivalent substitutions for some of the technical features; and these modifications, changes, or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention, and should all be covered within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.

Claims

1. An oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects, characterized in that, It is covered by a phospholipid membrane on the outside, and a polypeptide-supramolecular complex is embedded inside the phospholipid membrane; The polypeptide-supramolecular complex is obtained by freeze-drying a polypeptide after coating a first phospholipid with a supramolecular solution. Supramolecular solvents consist of hydrogen donors and hydrogen acceptors; The phospholipid membrane is formed from a second phospholipid.

2. The oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects according to claim 1, characterized in that, Based on parts by weight, the second phospholipid is 10-24 parts and the polypeptide-supramolecular complex is 12-76 parts; In the polypeptide-supramolecular complex, the polypeptide is 0.01 to 10 parts by weight, the supramolecular solvent is 10 to 60 parts by weight, and the first phospholipid is 2 to 6 parts by weight. And / or, the mass ratio of the polypeptide to the phospholipid is 1:(30~50); And / or, in the polypeptide-supramolecular complex, the mass ratio of the polypeptide to the supramolecular solvent is 1:(50~100).

3. The oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects according to claim 2, characterized in that, The polypeptide includes at least one of the following: octapeptide-1, glutathione, carnosine, nonapeptide-1, heptapeptide-3, hexapeptide-11, hexapeptide-9, oligopeptide-1, oligopeptide-3, oligopeptide-5, oligopeptide-6, tripeptide-1, tripeptide-1 copper, tripeptide-3, tripeptide-5, decapeptide-4, tetrapeptide-4, tetrapeptide-7, pentapeptide-18, pentapeptide-4, myristoyl pentapeptide-11, copper peptide-2, stearoyl tripeptide-1, acetyl heptapeptide-4, acetyl hexapeptide-3, acetyl hexapeptide-8, acetyl tetrapeptide-5, acetyl carnosine, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, palmitoyl pentapeptide-4, palmitoyl hexapeptide-12, and camellia polypeptide. And / or, the polypeptide is nonapeptide-1, palmitoyl tetrapeptide-7, palmitoyl pentapeptide-4, and camellia polypeptide; And / or, the mass ratio of the nonapeptide-1, the palmitoyl tetrapeptide-7, and the palmitoyl pentapeptide-4 is 528.4:40.6:2.18; And / or, the supramolecular solvent is composed of a hydrogen donor and a hydrogen acceptor in a molar ratio of (1~5):1; And / or, the hydrogen donor is an amino acid compound and / or a carboxylic acid compound; And / or, the amino acid compounds include glycine and / or L-serine; And / or, the carboxylic acid compound includes at least one of isostearic acid, decanoic acid, and lactic acid; And / or, the hydrogen acceptor is an alkaloid; And / or, the alkaloids include at least one of matrine, oxymatrine, betaine, carnitine, and choline.

4. The oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects according to claim 2, characterized in that, Phospholipids include at least one of soybean lecithin, egg yolk lecithin, hydrogenated lecithin, phosphatidylcholine, phosphatidylethanolamine, dipalmitoyl phosphatidylcholine, and distearate phosphatidylcholine; And / or, the phosphatidylcholine content of the soybean lecithin is ≥90%.

5. The oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects according to any one of claims 1 to 4, characterized in that, It also includes stabilizers in parts by weight of 1 to 15; And / or, the stabilizer includes at least one of triglyceride tri(ethylhexanoate), caprylic / capric triglyceride, squalane, camellia oil, vitamin E, and disodium EDTA; And / or, the oil-soluble polypeptide composition further includes 2 to 40 parts by weight of an adjuvant; And / or, the adjuvant includes at least one of 1,2-hexanediol, pentanediol, and butanediol.

6. A method for preparing an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects as described in any one of claims 1 to 4, characterized in that, The polypeptide is dissolved in a supramolecular solvent to obtain a supramolecular solution of the polypeptide. A first phospholipid is added to the supramolecular solution of the polypeptide and mixed evenly. Then, the polypeptide-supramolecular complex is obtained by freeze-drying. A phospholipid solution is obtained by mixing a second phospholipid, optional auxiliaries, and optional stabilizers; finally, the polypeptide-supramolecular complex is added to the phospholipid solution and mixed evenly to obtain an oil-soluble polypeptide composition.

7. The preparation method according to claim 6, characterized in that, The mass ratio of the first phospholipid to the second phospholipid is 1:(2~12).

8. The preparation method according to claim 6, characterized in that, The supramolecular solvent is prepared by grinding the hydrogen donor and hydrogen acceptor and dispersing them in an alcohol-water solution, and then reacting them under nitrogen protection to obtain the supramolecular solvent. And / or, in the aqueous alcohol solution, the concentration of alcohol is 50-70 wt%; And / or, the alcohol in the aqueous alcohol solution includes at least one of methanol, ethanol, propylene glycol, and butanediol; And / or, the reaction is carried out at a temperature of 20-45°C for a time of 20-36 hours.

9. The use of an oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects as described in any one of claims 1 to 4 in the preparation of cosmetics.

10. The application according to claim 9, characterized in that, The amount of oil-soluble polypeptide composition containing camellia polypeptide with cell-level anti-aging effects added to cosmetics is 0.5~10 wt%. And / or, the oil-soluble polypeptide composition is added during the cold preparation stage; And / or, the temperature of the cold preparation stage is below 50°C.

Images